Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 65343E108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Citigroup Inc.
13G
|
4.3% |
5/12/2025
Event 3/31/2025
|
||
| Citigroup Global Markets Inc. | 4.3% | |||
| Citigroup Financial Products Inc. | 4.3% | |||
| Citigroup Global Markets Holdings Inc. | 4.3% | |||
| Citigroup Inc. | 4.3% | |||
|
Pfizer Inc
13G/A
|
3.0% |
2/13/2026
Event 12/31/2025
|
||
| Pfizer Inc. (IRS Identification No.: 13-5315170) | 3.0% | |||
| Pfizer Ventures (US) LLC (IRS Indentification No. 82-5524518 ) | 2.5% | |||
|
Logos Global Management LP
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Logos Global Management LP | 0% | |||
| Logos Global Management GP LLC | 0% | |||
| Logos Global Master Fund LP | 0% | |||
| Logos GP LLC | 0% | |||
| Arsani William | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q3 | 1 | 21.8 k | $128 k |
| 2025 Q2 | 31 | 10.5 M | $5.65 M |
| 2025 Q1 | 40 | 15.4 M | $7.38 M |
| 2024 Q4 | 47 | 16.0 M | $13.1 M |
| 2024 Q3 | 46 | 15.9 M | $21.7 M |
| 2024 Q2 | 54 | 18.5 M | $29.4 M |
| 2024 Q1 | 52 | 16.9 M | $37.8 M |
| 2023 Q4 | 47 | 13.4 M | $15.4 M |
| 2023 Q3 | 44 | 12.9 M | $16.6 M |
| 2023 Q2 | 46 | 13.3 M | $24.0 M |
| 2023 Q1 | 47 | 13.3 M | $19.6 M |
| 2022 Q4 | 48 | 13.4 M | $19.0 M |
| 2022 Q3 | 57 | 15.2 M | $41.8 M |
| 2022 Q2 | 57 | 14.5 M | $68.2 M |
| 2022 Q1 | 62 | 13.2 M | $64.3 M |
| 2021 Q4 | 79 | 14.5 M | $87.2 M |
| 2021 Q3 | 74 | 14.7 M | $99.5 M |
| 2021 Q2 | 82 | 15.5 M | $124 M |
| 2021 Q1 | 98 | 18.0 M | $180 M |
| 2020 Q4 | 90 | 14.5 M | $159 M |
| 2020 Q3 | 81 | 18.3 M | $161 M |
| 2020 Q2 | 93 | 20.2 M | $434 M |
| 2020 Q1 | 89 | 20.3 M | $751 M |
| 2019 Q4 | 95 | 20.4 M | $1.15 B |
| 2019 Q3 | 54 | 11.3 M | $348 M |
| 2019 Q2 | 45 | 10.8 M | $161 M |